Aficamten

Aficamten (brand name MYQORZO™) is an FDA-approved, oral, selective cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by reducing excessive heart muscle contraction. It acts as an allosteric, reversible inhibitor, decreasing the number of active actin-myosin cross-bridges, which reduces left ventricular outflow tract (LVOT) gradients and improves functional capacity. Key features include a shallow dose-response relationship for easier titration and a favorable safety profile comparable to placebo, with no major reported drug-drug interactions.